News archive
Showing 644 results
February 2018
-
Media ReleaseNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis- Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows(1)- Study findings show absolute PASI ≤1/≤2/≤3…
-
Media ReleaseNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
-
Media ReleaseNovartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis- US label updated to include Cosentyx® (secukinumab) data in moderate to severe scalp psoriasis - one of the difficult-to-treat types of psoriasis(1,2)- Approximately half of all 125 million…
-
Media ReleaseNovartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
January 2018
-
Media ReleaseNovartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients-- Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara® (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks(1)-- Data…
-
Media ReleaseNovartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
-
Media ReleaseNovartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)- Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate…
-
Media ReleaseNovartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
-
Media ReleaseNovartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer- Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal…
-
Media ReleaseNovartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
December 2017
-
Media ReleaseNovartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS- Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions(1)- In a pivotal Phase III study, oral fingolimod significantly reduced relapses by 82%…
-
Media ReleaseNovartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS